Identification of Risk Factors, Exposomics and Genetic Susceptibility of Melanoma in Children, Adolescents and Young Adults
NCT ID: NCT06680323
Last Updated: 2024-11-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
200 participants
OBSERVATIONAL
2024-01-01
2026-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
MELCAYA - Novel Health Care Strategies for Melanoma in Children, Adolescents, and Young Adults - Work Package 3 (WP3)
NCT06602648
Impact of Anti PD-1 Therapy in Children, Adolescents and Young Adults (CAYA) Melanoma Patients
NCT06281912
Genetic Risk Factors and Acquired Oncogenic Mutations of Melanoma
NCT00849407
Precision Medicine for L/GCMN and Melanoma 1
NCT06608420
Study of Families With Melanoma
NCT00445783
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Classic melanoma
Classic malignant melanoma under the age of 30 years For patients with available biospecimen, the germline genome, transcriptome and in selected cases tumour normal exomes will be sequenced.
No interventions assigned to this group
Spitzoid melanoma
Spitzoid melanoma under the age of 30 years For patients with available biospecimen, the germline genome, transcriptome and in selected cases tumour normal exomes will be sequenced.
No interventions assigned to this group
Other melanoma
Other melanoma as melanoma on congenital nevi under the age of 30 years For patients with available biospecimen, the germline genome, transcriptome and in selected cases tumour normal exomes will be sequenced.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age until 30 years old
Exclusion Criteria
* no signed informed consent
30 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital Clinic of Barcelona
OTHER
University Of Perugia
OTHER
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
OTHER
Karolinska University Hospital
OTHER
Leibniz Research Institute for Environmental Medicine Düsseldorf
UNKNOWN
Princess Maxima Center for Pediatric Oncology
OTHER
Medical University of Gdansk
OTHER
University Hospital Tuebingen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Leibniz Research Institute for Environmental Medicine
Düsseldorf, , Germany
University of Florence
Florence, , Italy
Istituto Nazionale del Tumori
Milan, , Italy
Medical University of Gdánsk
Gdansk, , Poland
Hospital Clínic de Barcelona
Barcelona, , Spain
Karolinska Institute
Solna, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ewa Bien, MD, PhD
Role: primary
Susana Puig Sardá, MD, PhD
Role: primary
Hildur Helgadottir, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
834/2023BO2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.